Amicus Therapeutics Inc

Amicus Therapeutics insider sale: CEO sells 22,500 shares at near 52‑week high, yet retains a million‑share stake—signals confidence, liquidity strategy, and future growth prospects for rare disease pipeline.

Amicus Therapeutics CEO buys shares at 50% discount, boosting confidence in Phase‑3 mepolizumab for PKU; insider move signals potential breakthrough approval and market shift.